93292-85-4

Upstream product

• 100-39-0 benzyl bromide 
• 197229-61-1 (R)-5-(tert-Butyl-dimethyl-silanyloxy)-pentane-1,2-diol 
• 77697-15-5 (R)-(-)-γ-benzyloxymethyl-γ-butyrolactone 
• 93381-43-2 (R)-(-)-1-benzyloxy-2,5-pentanediol 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 93292-86-5 Acetic acid (R)-1-benzyloxymethyl-4-(tert-butyl-dimethyl-silanyloxy)-butyl ester 
• 85700-43-2 5E,7E-Clavulone II 
• 93292-88-7 Acetic acid (R)-1-benzyloxymethyl-4-oxo-butyl ester 
• 93292-87-6 Acetic acid (R)-1-benzyloxymethyl-4-hydroxy-butyl ester 
• 93292-89-8 (R)-4-Acetoxy-5-benzyloxy-pentanoic acid 
• 93292-90-1 (R)-4-Acetoxy-5-benzyloxy-pentanoic acid methyl ester 
• 338974-38-2 C₂₆H₄₀O₄Si 
• 1150576-77-4 octadecanoic acid (R)-1-(benzyloxy)-5-(tert-butyldimethylsilyloxy)pentan-2-yl ester 

Relevant academic research and scientific papers

Drug delivery by an enzyme-mediated cyclization of a lipid prodrug with unique bilayer-formation properties

Special delivery: Liposomal drug-delivery systems in which prodrugs are activated specifically by disease-associated enzymes have great potential for the treatment of severe diseases, such as cancer. A new type of phospholipid-based prodrug has the ability to form stable small unilamellar vesicles (see picture). Activation of the prodrug vesicles by the enzyme sPLA2 initiates a cyclization reaction, which leads to the release of the drug.

PYRAZOLE BASED LXR MODULATORS

Compounds of the invention, such as compounds of Formulae Ia, Ib, Ic, or Id and pharmaceutically acceptable salts, isomers, and prodrugs thereof, which are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3, and G are defined

TOTAL SYNTHESIS OF MARINE PROSTANOIDS CLAVULONES

An enantioselective and stereoselective synthesis of novel marine prostanoids clavulone II (1) and 12-O-desacetylclavulone II (2) has been accomplished.